Payment overview · 2025
General Payments
$1,554.81
18 reported records · 6 companies
Healthcare provider profile · identity verified
Heather Bunch
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · CHARLESTON, SC · NPI 1447942479
Verified facts
What the public records show
CMS Open Payments records show Heather Bunch received $1,554.81 in general payments during 2025 across 18 reported records.
Enterra Medical, Inc. accounted for 80.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Enterra Medical, Inc. | Unresolved — no canonical attribution shown | $1,243.82 | 80.0% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.26 | 9.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.63 | 5.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $40.39 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.46 | 1.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.25 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,085.72 | 15 |
| Travel and Lodging | $469.09 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $88.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $4.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 81 |
| Losartan Potassium | Losartan Potassium | 207 | 58 |
| Lisinopril | Lisinopril | 184 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 33 |
| Omeprazole | Omeprazole | 131 | 44 |
| Metformin Hcl | Metformin Hcl | 86 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 29 |
| Jardiance | Empagliflozin | 81 | 28 |
| Metformin Hcl Er | Metformin Hcl | 80 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 33 |
| Ezetimibe | Ezetimibe | 72 | 26 |
| Simvastatin | Simvastatin | 64 | 22 |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Ozempic | Semaglutide | 59 | 13 |
| Furosemide | Furosemide | 58 | 21 |
| Sertraline Hcl | Sertraline Hcl | 58 | 20 |
| Trazodone Hcl | Trazodone Hcl | 54 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Potassium Chloride | Potassium Chloride | 53 | 19 |
| Alendronate Sodium | Alendronate Sodium | 51 | 13 |
| Carvedilol | Carvedilol | 51 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 14 |
| Allopurinol | Allopurinol | 44 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 14 |
| Famotidine | Famotidine | 43 | 17 |
| Farxiga | Dapagliflozin Propanediol | 43 | 14 |
| Gabapentin | Gabapentin | 41 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Meloxicam | Meloxicam | 34 | 15 |
| Valsartan | Valsartan | 34 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 11 |
| Fenofibrate | Fenofibrate | 29 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Prednisone | Prednisone | 24 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Linzess | Linaclotide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,554.81 · 18 records | Enterra Medical, Inc. | CREON, GATTEX, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error